CN113398209B - Compound traditional Chinese medicine for intervening hepatic fibrosis as well as preparation method and application thereof - Google Patents

Compound traditional Chinese medicine for intervening hepatic fibrosis as well as preparation method and application thereof Download PDF

Info

Publication number
CN113398209B
CN113398209B CN202110721678.9A CN202110721678A CN113398209B CN 113398209 B CN113398209 B CN 113398209B CN 202110721678 A CN202110721678 A CN 202110721678A CN 113398209 B CN113398209 B CN 113398209B
Authority
CN
China
Prior art keywords
parts
raw
traditional chinese
chinese medicine
vinegar
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202110721678.9A
Other languages
Chinese (zh)
Other versions
CN113398209A (en
Inventor
景燕燕
李卫强
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ningxia Medical University
Original Assignee
Ningxia Medical University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ningxia Medical University filed Critical Ningxia Medical University
Priority to CN202110721678.9A priority Critical patent/CN113398209B/en
Publication of CN113398209A publication Critical patent/CN113398209A/en
Application granted granted Critical
Publication of CN113398209B publication Critical patent/CN113398209B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/58—Reptiles
    • A61K35/583—Snakes; Lizards, e.g. chameleons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/58—Reptiles
    • A61K35/586—Turtles; Tortoises, e.g. terrapins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/07—Basidiomycota, e.g. Cryptococcus
    • A61K36/074—Ganoderma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/07—Basidiomycota, e.g. Cryptococcus
    • A61K36/076—Poria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/232—Angelica
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/233—Bupleurum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/284—Atractylodes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/483—Gleditsia (locust)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/484—Glycyrrhiza (licorice)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/537—Salvia (sage)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/66—Papaveraceae (Poppy family), e.g. bloodroot
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A61K36/734—Crataegus (hawthorn)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/75—Rutaceae (Rue family)
    • A61K36/752—Citrus, e.g. lime, orange or lemon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
    • A61K36/815—Lycium (desert-thorn)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The invention relates to the technical field of traditional Chinese medicines, in particular to a compound traditional Chinese medicine for intervening hepatic fibrosis and a preparation method thereof, wherein the compound traditional Chinese medicine comprises the following raw materials in parts by weight: 10-30 parts of lizard, 10-30 parts of angelica sinensis rootlets, 10-20 parts of vinegar-processed radix bupleuri, 10-30 parts of raw white peony roots, 20-50 parts of raw bighead atractylodes rhizome, 10-30 parts of poria cocos, 10-30 parts of vinegar-processed turtle shells, 20-50 parts of salvia miltiorrhiza, 15-45 parts of red paeony roots, 10-30 parts of liquorice, 20-50 parts of raw rice sprouts, 20-40 parts of raw hawthorns, 10-30 parts of rhizoma corydalis, 10-30 parts of deerhorn glue, 20-50 parts of spina gleditsiae, 20-50 parts of lucid ganoderma, 10-30 parts of medlar, 10-30 parts of fingered citron and 10-30 parts of dark plums. The compound preparation has remarkable curative effect on hepatic fibrosis caused by liver blood deficiency and vein stasis.

Description

Compound traditional Chinese medicine for intervening hepatic fibrosis as well as preparation method and application thereof
Technical Field
The invention relates to the technical field of traditional Chinese medicines, in particular to a compound traditional Chinese medicine for intervening hepatic fibrosis and a preparation method and application thereof.
Background
Liver fibrosis (HF) is a pathological change that is present in most chronic liver disease processes, mainly manifested by excessive proliferation and deposition of extracellular matrix (ECM) within liver tissue, formation of liver collagen fibers, alteration of liver tissue structure, and affecting its normal physiological function. HA, LN, PC-III and IV-C are all important components of ECM, when hepatic fibrosis occurs, the contents of HA, LN, PC-III and IV-C in serum will be increased correspondingly, which not only can be used for clinical detection of hepatic fibrosis, but also can express the severity of hepatic fibrosis. There is currently a lack of a drug that can effectively treat HF.
Disclosure of Invention
The invention aims to provide a compound traditional Chinese medicine for intervening hepatic fibrosis and a preparation method thereof.
In order to achieve the above object, the present invention provides the following technical solutions:
a compound traditional Chinese medicine for intervening hepatic fibrosis is prepared from the following raw materials in parts by weight: 10-30 parts of lizard, 10-30 parts of angelica sinensis rootlets, 10-20 parts of vinegar-processed radix bupleuri, 10-30 parts of raw white peony roots, 20-50 parts of raw bighead atractylodes rhizome, 10-30 parts of poria cocos, 10-30 parts of vinegar-processed turtle shells, 20-50 parts of salvia miltiorrhiza, 15-45 parts of red paeony roots, 10-30 parts of liquorice, 20-50 parts of raw rice sprouts, 20-40 parts of raw hawthorns, 10-30 parts of rhizoma corydalis, 10-30 parts of deerhorn glue, 20-50 parts of spina gleditsiae, 20-50 parts of lucid ganoderma, 10-30 parts of medlar, 10-30 parts of fingered citron and 10-30 parts of dark plums.
Preferably, the feed additive comprises the following raw materials in parts by weight: 15 parts of lizard, 10 parts of Chinese angelica root, 10 parts of vinegar radix bupleuri, 10 parts of raw white peony root, 20 parts of raw bighead atractylodes rhizome, 10 parts of poria cocos, 10 parts of vinegar turtle shell, 20 parts of salvia miltiorrhiza, 15 parts of red paeony root, 10 parts of liquorice, 20 parts of raw rice sprout, 20 parts of raw hawthorn, 10 parts of rhizoma corydalis, 10 parts of deer-horn glue, 20 parts of spina gleditsiae, 20 parts of lucid ganoderma, 10 parts of medlar, 10 parts of fingered citron and 20 parts of dark plum.
Preferably, the feed additive comprises the following raw materials in parts by weight: 20 parts of lizard, 20 parts of angelica sinensis rootlets, 15 parts of vinegar radix bupleuri, 20 parts of raw white peony roots, 30 parts of raw bighead atractylodes rhizome, 15 parts of poria cocos, 15 parts of vinegar turtle shells, 30 parts of salvia miltiorrhiza, 30 parts of red paeony roots, 20 parts of liquorice, 30 parts of raw rice sprouts, 30 parts of raw hawthorns, 25 parts of rhizoma corydalis, 20 parts of deer-horn glue, 30 parts of spina gleditsiae, 30 parts of lucid ganoderma, 20 parts of medlar, 20 parts of fingered citron and 20 parts of dark plums.
Preferably, the feed additive comprises the following raw materials in parts by weight: 30 parts of lizard, 30 parts of Chinese angelica root, 20 parts of vinegar radix bupleuri, 30 parts of raw white peony root, 45 parts of raw bighead atractylodes rhizome, 30 parts of poria cocos, 30 parts of vinegar turtle shell, 45 parts of red sage root, 45 parts of red peony root, 20 parts of liquorice, 40 parts of raw rice sprout, 40 parts of raw hawthorn, 30 parts of rhizoma corydalis, 30 parts of deer-horn glue, 40 parts of spina gleditsiae, 40 parts of lucid ganoderma, 30 parts of Chinese wolfberry, 30 parts of fingered citron and 30 parts of dark plum.
The invention also provides a preparation method of the compound traditional Chinese medicine for intervening hepatic fibrosis, which comprises the following specific steps:
step 1, weighing lizard, Chinese angelica whiskers, vinegar-processed radix bupleuri, raw white paeony root, raw bighead atractylodes rhizome, poria cocos, vinegar-processed turtle shell, salvia miltiorrhiza, red paeony root, liquorice, raw rice sprouts, raw hawthorn, rhizoma corydalis, deer-horn glue, spina gleditsiae, lucid ganoderma, medlar, fingered citron and dark plum in parts by weight, and drying for later use;
and 2, crushing the weighed traditional Chinese medicine raw materials into fine powder, and mixing to obtain the compound traditional Chinese medicine.
Preferably, the compound traditional Chinese medicine can be further prepared into a pharmaceutically acceptable oral preparation.
Preferably, the oral formulation is a gel formulation.
Preferably, the gel preparation is prepared according to the following method:
step 1, mixing pectin and 20-25 times of water, and heating to dissolve the pectin to form a pectin sticky body;
step 2, mixing the compound traditional Chinese medicine and the pectin sticky body according to the mass ratio of 1:2.5-10 to obtain a mixture;
and 3, sterilizing the mixture, sequentially pressing the mixture into a die and packaging the die to obtain the gel preparation.
The gel preparation can be used for preparing medicines for treating hepatic fibrosis due to liver blood deficiency and vein stasis.
The liver governs storing blood and is called blood sea, which governs regulating qi and is the hub of qi. Based on yin and blood, the liver maintains its function of dispersing qi, manifesting its yin-yang property. When the liver stores sufficient blood, it can nourish the liver, so that the liver qi is abundant and regulated to play the role of normal smoothing flow of qi. Therefore, the function of liver in dispersing qi movement depends on yin blood in liver, so when liver is damaged by drugs, alcohol, virus and other factors, it may cause liver blood deficiency, liver failure to nourish liver, liver softness, liver qi stagnation, blood stasis and obstruction, and hypochondriac pain, even mass. The basic pathogenesis of hepatic fibrosis is liver blood deficiency and vein stasis.
The invention is based on modern medicine, takes the theory of traditional Chinese medicine as guidance, takes the properties of liver yin for yang, governing smoothing flow of qi and storing blood, mainly takes nourishing liver and blood, and also has the functions of dredging collaterals and dissipating stagnation, and is different from the prior single medicine for promoting blood circulation and removing blood stasis. The method comprises the following steps: lizard is taken as a monarch product with emotion in blood and meat, and cultured in a simulated sand environment, and has the effects of nourishing blood, dredging collaterals and dissipating stagnation; the ministerial drugs comprise angelica sinensis, deerhorn glue and medlar, warm the liver, nourish the liver, promote blood circulation and remove meridian obstruction, and salvia miltiorrhiza, red paeony root, vinegar turtle shell and spina gleditsiae, so as to remove blood stasis, dissipate stagnation and relieve pain; the vinegar radix bupleuri, the fingered citron and the rhizoma corydalis have the effects of soothing the liver and regulating the flow of qi, the raw white paeony root and the dark plum have the effects of astringing the liver and nourishing yin, and the raw bighead atractylodes rhizome, the tuckahoe, the raw rice sprout, the raw hawthorn and the lucid ganoderma have the effects of strengthening the spleen and promoting the circulation of liver blood; the liquorice is used for harmonizing the medicines. The whole formula can nourish liver blood, soften liver body, warm and nourish liver qi, is matched with the functions of removing blood stasis and dredging collaterals, regulating yin and yang, treating both qi and blood, and preventing and treating hepatic fibrosis caused by blood deficiency and collateral stasis, and has obvious curative effect.
The angelica sinensis whiskers can treat various symptoms caused by blood deficiency, and can play a good role in nourishing liver blood when being used together with antler glue and medlar, and the angelica sinensis whiskers contain angelica sinensis polysaccharide which has a good liver protection effect and can change the levels of erythropoietin and hepcidin in the liver, so that the angelica sinensis whiskers have a certain regulation effect on blood deficiency anemia; because of the homology of qi and blood, the effects of tonifying qi and blood and achieving twice the result with half the effort can be achieved by combining the qi-tonifying product ganoderma lucidum with the blood-tonifying product;
the vinegar radix bupleuri has the effects of soothing liver and relieving depression, and the main chemical component of the vinegar radix bupleuri is triterpenoid compound saikoside, has the effects of resisting inflammation and resisting liver injury, and can play a good role in combing liver qi by being matched with the liver-soothing and qi-regulating fingered citron and the blood-activating and qi-moving rhizoma corydalis;
the salvia miltiorrhiza, radix paeoniae rubra, blood cooling, blood circulation activating, stasis dissipating and pain relieving, the vinegar turtle shell, yin nourishing, yang suppressing, hardness softening and stagnation dissipating, the lizard, which is a product with the emotion of blood and meat, has the effects of tonifying deficiency, activating blood and removing blood stasis, and the spina gleditsiae, which belongs to the liver and stomach channels, is matched to reduce swelling and expel pus, and the four medicines are used together, so that the vinegar turtle shell, the lizard and the like have good effects of activating the liver and activating collaterals, removing blood stasis and promoting tissue regeneration. In addition, because the liver is just the zang organ, yin of the body and yang of the body, a large amount of bitter and cold drugs are not used to damage liver yang and liver qi in the medication, attention should be paid to the function of reciting liver to store blood, and turtle shells for nourishing yin and suppressing yang and lizard for promoting blood circulation and enriching blood have better curative effects in the treatment of blood deficiency and collateral stasis type liver fibrosis and other abdominal mass diseases;
the raw white peony root can nourish blood and soften liver, and relieve and stop pain, and the dark plum has the effects of astringing liver yin and softening liver when being matched with the raw white peony root, and modern researches also show that paeoniflorin can play a role in protecting inflammatory liver injury by regulating a channel between IkB and NF-kB;
for liver diseases, the liver is known to transmit spleen, and when the spleen is strengthened, raw white atractylodes rhizome is used together with tuckahoe to strengthen spleen, dry dampness and promote diuresis, so as to prevent diseases and prevent diseases from being deteriorated without being affected by pathogenic factors;
in addition, in the prescription, not only the change of diseases per se is considered, but also the absorption and utilization conditions of the body to the medicine are considered, the spleen and stomach are the acquired root, nutrient substances in food and effective components in the medicine are absorbed and utilized by the transportation and transformation functions of the spleen and the stomach, raw rice sprout and raw hawthorn are used for promoting digestion and tonifying the spleen, the medicine can be better absorbed and utilized, the raw hawthorn can enter the liver channel and enter the blood system, the blood circulation is promoted to remove blood stasis, blood stasis is removed without hurting new blood, the treatment idea of nourishing the liver blood and dredging the liver collaterals of the formula is met, and finally the liquorice is used for regulating the medicines, so that the liver fibrosis with liver blood deficiency and vein stasis is treated totally, and the curative effect is obvious.
Compared with the prior art, the invention has the beneficial effects that:
1. the compound traditional Chinese medicine provided by the invention can reduce the fibrosis degree of liver tissues and inhibit or reverse the formation of collagen fibers by influencing important components of ECM such as HA, LN, PC-III, IV-C and the like, and HAs better anti-hepatic fibrosis effect.
2. The gel preparation prepared from the compound traditional Chinese medicine provided by the invention has the advantages of simple preparation method, convenience for carrying, good biocompatibility, slow release effect on medicine release and good curative effect when being applied to clinical diagnosis and treatment of diseases; meanwhile, the gel preparation can also improve the bioavailability of the raw material medicines, reduce the dosage and save the traditional Chinese medicine resources.
3. The invention provides a pure Chinese medicinal preparation with small side effect.
Drawings
FIG. 1 shows the change of liver fibrosis degree (Masson X100) under a light microscope for each group of mice;
FIG. 2 shows the result of analyzing the content of collagen fibers in liver tissues of mice in each group by using Image J software;
FIG. 3 shows the measurement results of the HA content in the serum of each group of mice;
FIG. 4 shows the measurement results of LN content in serum of each group of mice;
FIG. 5 shows the measurement results of the content of PC-III in serum of each group of mice;
FIG. 6 shows the results of the measurement of the C-IV content in the serum of each group of mice;
wherein, in fig. 1-6: a is a blank group; b is a model group; c is an Anluo chemical fiber group; d is a compound Chinese medicinal low concentration group; e is a concentration group in the compound traditional Chinese medicine; f is a compound Chinese medicinal high concentration group; in comparison with the blank set, the results,*P<0.05，**P<0.01; in comparison with the set of models,△P<0.05，△△P<0.01。
Detailed Description
The technical solution of the present invention will be described in further detail with reference to specific examples. It is to be understood that the described embodiments are merely exemplary of the invention, and not restrictive of the full scope of the invention. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
Example 1
A compound traditional Chinese medicine for intervening hepatic fibrosis is prepared from the following raw materials: 10g of lizard, 10g of Chinese angelica root, 10g of vinegar-processed radix bupleuri, 10g of raw white peony root, 20g of raw bighead atractylodes rhizome, 10g of poria cocos, 10g of vinegar-processed turtle shell, 20g of salvia miltiorrhiza, 15g of red paeony root, 10g of liquorice, 20g of raw rice sprout, 20g of raw hawthorn, 10g of rhizoma corydalis, 10g of deerhorn glue, 20g of spina gleditsiae, 20g of lucid ganoderma, 10g of medlar, 10g of fingered citron and 10g of dark plum.
Example 2
A compound traditional Chinese medicine for intervening hepatic fibrosis is prepared from the following raw materials: 15g of lizard, 10g of Chinese angelica root, 10g of vinegar-processed radix bupleuri, 10g of raw white peony root, 20g of raw bighead atractylodes rhizome, 10g of poria cocos, 10g of vinegar-processed turtle shell, 20g of salvia miltiorrhiza, 15g of red paeony root, 10g of liquorice, 20g of raw rice sprout, 20g of raw hawthorn, 10g of rhizoma corydalis, 10g of deerhorn glue, 20g of spina gleditsiae, 20g of lucid ganoderma, 10g of medlar, 10g of fingered citron and 20g of dark plum.
Example 3
A compound traditional Chinese medicine for intervening hepatic fibrosis is prepared from the following raw materials: 20g of lizard, 20g of Chinese angelica root, 15g of vinegar-processed radix bupleuri, 20g of raw white peony root, 30g of raw bighead atractylodes rhizome, 15g of poria cocos, 15g of vinegar-processed turtle shell, 30g of red sage root, 30g of red peony root, 20g of liquorice, 30g of raw rice sprout, 30g of raw hawthorn, 25g of rhizoma corydalis, 20g of deer-horn glue, 30g of spina gleditsiae, 30g of lucid ganoderma, 20g of Chinese wolfberry, 20g of fingered citron and 20g of dark plum.
Example 4
A compound traditional Chinese medicine for intervening hepatic fibrosis is prepared from the following raw materials: 30g of lizard, 30g of Chinese angelica root, 20g of vinegar-processed radix bupleuri, 30g of raw white peony root, 45g of raw bighead atractylodes rhizome, 30g of poria cocos, 30g of vinegar-processed turtle shell, 45g of red sage root, 45g of red peony root, 20g of liquorice, 40g of raw rice sprout, 40g of raw hawthorn, 30g of rhizoma corydalis, 30g of deerhorn glue, 40g of spina gleditsiae, 40g of lucid ganoderma, 30g of Chinese wolfberry, 30g of fingered citron and 30g of dark plum.
Example 5
A compound traditional Chinese medicine for intervening hepatic fibrosis is prepared from the following raw materials: 20g of lizard, 25g of Chinese angelica root, 15g of vinegar-processed radix bupleuri, 10g of raw white peony root, 50g of raw bighead atractylodes rhizome, 15g of poria cocos, 20g of vinegar-processed turtle shell, 50g of red sage root, 35g of red peony root, 30g of liquorice, 50g of raw rice sprout, 30g of raw hawthorn, 25g of rhizoma corydalis, 25g of deer-horn glue, 50g of spina gleditsiae, 50g of lucid ganoderma, 2g of Chinese wolfberry, 20g of fingered citron and 30g of dark plum.
The preparation method of the above examples 1 to 5 is as follows: weighing radix Angelicae sinensis, radix bupleuri processed with vinegar, radix Paeoniae alba, rhizoma Atractylodis Macrocephalae processed, Poria processed, carapax Trionycis processed with vinegar, radix Salviae Miltiorrhizae, radix Paeoniae Rubra, radix Glycyrrhizae processed, fructus Setariae Germinatus processed, fructus crataegi processed, rhizoma corydalis processed, colla cornus cervi processed, spina Gleditsiae processed, Ganoderma processed, fructus Lycii processed, fructus Citri Sarcodactylis processed, and fructus mume processed by oven drying, pulverizing, sieving with 80 mesh sieve, and mixing the obtained fine powders.
The compound traditional Chinese medicine can be further prepared into pharmaceutically acceptable oral preparations, such as capsules, tablets, oral liquid, gel preparations and the like. The further preparation method of the compound traditional Chinese medicine is illustrated by taking a gel preparation as an example, and comprises the following steps:
step 1, mixing edible pectin and 20 times of water, heating to dissolve the pectin to form a pectin sticky body, and using the pectin sticky body as a carrier of a gel preparation for later use;
step 2, mixing the compound traditional Chinese medicine and the pectin sticky body according to a mass ratio of 1:2.5-10 to obtain a mixture;
step 3, putting the mixture obtained in the step 2 into a high-pressure-resistant mold, heating and sterilizing by high-pressure steam, recovering to room temperature, and taking out from the mold to obtain a gel preparation;
and 4, packaging the gel preparation obtained in the step 3 with wax paper, preservative film or tinfoil paper, and storing in a cool and dry place.
Since the effects of the compound traditional Chinese medicines for treating hepatic fibrosis prepared in examples 1 to 5 are substantially the same, the effect will be described below by taking the compound traditional Chinese medicine prepared in example 4 as an example.
1. Method of producing a composite material
4 w-old ICR mice were acclimatized for 7 days and randomized into blanks (10) and building blocks (50). The mouse model was constructed by intraperitoneal injection of a 10% volume carbon tetrachloride solution (prepared from carbon tetrachloride corn oil at a ratio of 1: 9) at a dose of 5ml/kg, 2 times/w, and 8w per injection to create an HF model. The mice in the blank group were injected with an equal volume of normal saline intraperitoneally (i.p.) for 2 times/w for 8 w. After 8w, 3 mice were randomly drawn from each group and subjected to four liver fibrosis and liver tissue HE staining tests, showing that the establishment of CCL 4-induced mouse HF model was successful.
Mice successfully modeled were randomly divided into a model group, an Anluo chemical fiber group (10mg/ml Anluo chemical fiber pill: 6 g/bag in specification, lot number: 2070600, Senlong pharmaceutical Co., Ltd.), and a Chinese herbal compound low (2g/ml), medium (4g/ml), high concentration group (8g/ml), each group was gavaged for 1 time/d, 10ml/kg each time, and 4w of drug was continuously administered. Blank control group and model control group were given equal volume of physiological saline at 1 time/day for 4 w. Taking materials, and detecting indexes.
2. Results
2.1 Effect of the compound traditional Chinese medicine on the general conditions of liver fibrosis mice
In the experiment, the blank group of mice is found to have good growth state, acute response to external stimulation, vitality in eyes, bright hair, normal increase of diet and weight and no death condition; compared with the blank group, the model group mice grow slowly, move slowly, have no spirit in eyes, and have yellow and withered fur, and most of the mice in the later period of the model group have the conditions of inappetence, hair explosion, emaciation and the like; after 4 weeks of drug intervention, the body weight of mice in each group except the model group gradually recovered and increased, the food intake and the drinking water were also increased to a certain extent, and the hair color condition was also improved to a certain extent.
2.2 Effect of the compound traditional Chinese medicine on the degree of fibrosis of liver tissues of liver fibrosis mice
As shown in fig. 1. The blank control group mice have normal hepatocyte structure and normal lobular structure, and no obvious collagen fiber hyperplasia; the liver histiocyte of the mouse in the model group has edema, vacuole-like change and inflammatory cell infiltration to different degrees, the lobular structure of the liver is destroyed, the arrangement is disordered and the fibroplasia is generated; when the compound traditional Chinese medicine is used for treating each group, the damage of the liver structure is gradually improved along with the increase of the dosage, the degrees of liver cell edema, fatty lesion and inflammatory cell infiltration are obviously reduced, and the deposition of collagen fibers and the proliferation of connective tissues are obviously reduced.
The content of collagen fibers in liver tissues of each group of mice was analyzed by using Image J software, and the results showed that (see fig. 2): compared with the blank group, the content of the collagen fiber in the liver tissue of the model group mouse is obviously increased (P is less than 0.01); compared with the model group, the content of collagen fibers in liver tissues of mice in the Anluohuaxian fiber group and the compound traditional Chinese medicine high, medium and low concentration intervention group is obviously reduced (P is less than 0.01).
2.3 the influence of the compound traditional Chinese medicine on the blood serum HA, LN, PC-III and C-IV of the hepatic fibrosis mice
The main pathological manifestations of HF are the growth of hepatic collagen fibers and the deposition of the extracellular matrix (ECM) of the liver, while HA, LN, PC-III and IV-C are important constituents of ECM, and their levels are closely related to the process of ECM accumulation and collagen crosslinking into fibers, so that when HF occurs, HA, LN, PC-III and C-IV in the serum will rise, reflecting the severity of hepatic fibrosis.
As shown in fig. 3-6. Compared with a blank group, the serum levels of HA, LN, PC-III and C-IV of the model group mice are all obviously increased (P is less than 0.01); compared with the model group, the levels of HA, LN, PC-III and C-IV in the serum of mice in the Anluohuaxian group and the compound traditional Chinese medicine high, medium and low concentration intervention group are all obviously reduced (P is less than 0.01). The compound traditional Chinese medicine provided by the invention can obviously relieve liver tissue fibrosis.
The foregoing is only a preferred embodiment of the present invention, and it should be noted that, for those skilled in the art, various modifications and decorations can be made without departing from the principle of the present invention, and these modifications and decorations should also be regarded as the protection scope of the present invention.

Claims (10)

1. The compound traditional Chinese medicine for intervening hepatic fibrosis is characterized by comprising the following raw materials in parts by weight: 10-30 parts of lizard, 10-30 parts of angelica sinensis rootlets, 10-20 parts of vinegar-processed radix bupleuri, 10-30 parts of raw white peony roots, 20-50 parts of raw bighead atractylodes rhizome, 10-30 parts of poria cocos, 10-30 parts of vinegar-processed turtle shells, 20-50 parts of salvia miltiorrhiza, 15-45 parts of red paeony roots, 10-30 parts of liquorice, 20-50 parts of raw rice sprouts, 20-40 parts of raw hawthorns, 10-30 parts of rhizoma corydalis, 10-30 parts of deerhorn glue, 20-50 parts of spina gleditsiae, 20-50 parts of lucid ganoderma, 10-30 parts of medlar, 10-30 parts of fingered citron and 10-30 parts of dark plums.
2. The compound traditional Chinese medicine for intervening hepatic fibrosis of claim 1, which is prepared from the following raw materials in parts by weight: 15 parts of lizard, 10 parts of Chinese angelica root, 10 parts of vinegar radix bupleuri, 10 parts of raw white peony root, 20 parts of raw bighead atractylodes rhizome, 10 parts of poria cocos, 10 parts of vinegar turtle shell, 20 parts of salvia miltiorrhiza, 15 parts of red paeony root, 10 parts of liquorice, 20 parts of raw rice sprout, 20 parts of raw hawthorn, 10 parts of rhizoma corydalis, 10 parts of deer-horn glue, 20 parts of spina gleditsiae, 20 parts of lucid ganoderma, 10 parts of medlar, 10 parts of fingered citron and 20 parts of dark plum.
3. The compound traditional Chinese medicine for intervening hepatic fibrosis of claim 1, which is prepared from the following raw materials in parts by weight: 20 parts of lizard, 20 parts of angelica sinensis rootlets, 15 parts of vinegar radix bupleuri, 20 parts of raw white peony roots, 30 parts of raw bighead atractylodes rhizome, 15 parts of poria cocos, 15 parts of vinegar turtle shells, 30 parts of salvia miltiorrhiza, 30 parts of red paeony roots, 20 parts of liquorice, 30 parts of raw rice sprouts, 30 parts of raw hawthorns, 25 parts of rhizoma corydalis, 20 parts of deer-horn glue, 30 parts of spina gleditsiae, 30 parts of lucid ganoderma, 20 parts of medlar, 20 parts of fingered citron and 20 parts of dark plums.
4. The compound traditional Chinese medicine for intervening hepatic fibrosis of claim 1, which is prepared from the following raw materials in parts by weight: 30 parts of lizard, 30 parts of Chinese angelica root, 20 parts of vinegar radix bupleuri, 30 parts of raw white peony root, 45 parts of raw bighead atractylodes rhizome, 30 parts of poria cocos, 30 parts of vinegar turtle shell, 45 parts of red sage root, 45 parts of red peony root, 20 parts of liquorice, 40 parts of raw rice sprout, 40 parts of raw hawthorn, 30 parts of rhizoma corydalis, 30 parts of deer-horn glue, 40 parts of spina gleditsiae, 40 parts of lucid ganoderma, 30 parts of Chinese wolfberry, 30 parts of fingered citron and 30 parts of dark plum.
5. The preparation method of the compound traditional Chinese medicine for intervening hepatic fibrosis, which is disclosed by any one of claims 1 to 4, is characterized by comprising the following steps:
step 1, weighing lizard, Chinese angelica whiskers, vinegar-processed radix bupleuri, raw white paeony root, raw bighead atractylodes rhizome, poria cocos, vinegar-processed turtle shell, salvia miltiorrhiza, red paeony root, liquorice, raw rice sprouts, raw hawthorn, rhizoma corydalis, deer-horn glue, spina gleditsiae, lucid ganoderma, medlar, fingered citron and dark plum in parts by weight, and drying for later use;
and 2, crushing the weighed traditional Chinese medicine raw materials into fine powder, and mixing to obtain the compound traditional Chinese medicine.
6. The preparation method of claim 5, wherein the compound traditional Chinese medicine is prepared into a pharmaceutically acceptable oral preparation.
7. The method of claim 6, wherein the oral formulation is a gel formulation.
8. The method of claim 7, wherein the gel formulation is prepared by the following method:
step 1, mixing pectin and 20-25 times of water, and heating to dissolve the pectin to form a pectin sticky body;
step 2, mixing the compound traditional Chinese medicine and the pectin sticky body according to the mass ratio of 1:2.5-10 to obtain a mixture;
and 3, sterilizing the mixture, sequentially pressing the mixture into a die and packaging the die to obtain the gel preparation.
9. A gel preparation obtained by the production method according to claim 8.
10. Use of the gel formulation of claim 9 in the manufacture of a medicament for the treatment of hepatic fibrosis due to liver blood deficiency and vein stasis.
CN202110721678.9A 2021-06-28 2021-06-28 Compound traditional Chinese medicine for intervening hepatic fibrosis as well as preparation method and application thereof Active CN113398209B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110721678.9A CN113398209B (en) 2021-06-28 2021-06-28 Compound traditional Chinese medicine for intervening hepatic fibrosis as well as preparation method and application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202110721678.9A CN113398209B (en) 2021-06-28 2021-06-28 Compound traditional Chinese medicine for intervening hepatic fibrosis as well as preparation method and application thereof

Publications (2)

Publication Number Publication Date
CN113398209A CN113398209A (en) 2021-09-17
CN113398209B true CN113398209B (en) 2022-04-12

Family

ID=77679896

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202110721678.9A Active CN113398209B (en) 2021-06-28 2021-06-28 Compound traditional Chinese medicine for intervening hepatic fibrosis as well as preparation method and application thereof

Country Status (1)

Country Link
CN (1) CN113398209B (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102389496A (en) * 2011-11-16 2012-03-28 蚌埠丰原涂山制药有限公司 Chinese medical composition for treating hepatitis and preparation method thereof
CN110731972A (en) * 2019-12-04 2020-01-31 黑龙江中医药大学 Application of extracts in preparing anti-hepatic fibrosis medicine and composition thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102389496A (en) * 2011-11-16 2012-03-28 蚌埠丰原涂山制药有限公司 Chinese medical composition for treating hepatitis and preparation method thereof
CN110731972A (en) * 2019-12-04 2020-01-31 黑龙江中医药大学 Application of extracts in preparing anti-hepatic fibrosis medicine and composition thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
七味化纤汤对慢性乙型肝炎患者抗纤维化作用的临床及组织学研究;唐金模等;《中医杂志》;20030731;第44卷(第7期);第514-516页 *
中药治疗肝纤维化的用药规律研究;罗茂权等;《广西医学》;20210131;第43卷(第1期);第52-55、136页 *
丹柴君子汤对损伤性肝脏血流动力学影响的实验研究;薛建国等;《中华肝胆外科杂志》;20051231;第11卷(第12期);第811、820页 *
逍遥散防治肝纤维化的实验研究;朱光泽等;《吉林中医药》;20021130;第22卷(第6期);第53-54页 *

Also Published As

Publication number Publication date
CN113398209A (en) 2021-09-17

Similar Documents

Publication Publication Date Title
CN103860958B (en) A kind of Chinese medicine composition for treating acne
CN103720769A (en) Traditional Chinese medicinal composition capable of enhancing immunity
CN107952040A (en) For nursing one&#39;s health the Chinese herbal ointment formula and its processing method of obstruction of the circulation of vital energy constitution
CN101411826A (en) Internal-use medicament for treating psoriasis
CN108670933A (en) Have both moisturizing, the skin care compositions of whitening and anti-aging and its application
CN102935133A (en) Traditional Chinese medicine composition for treating rheumatic arthritis as well as preparation method and application thereof
CN113398209B (en) Compound traditional Chinese medicine for intervening hepatic fibrosis as well as preparation method and application thereof
CN1330345C (en) Combination of Chinese traditional medicine for treating hyperlipemia, and preparation method
CN105963467A (en) Traditional Chinese medicine composition, application thereof and preparation
CN105250495A (en) Traditional Chinese medicine composition for protecting liver
CN103565987A (en) Traditional Chinese medicine powder for treating silky coccidiosis
CN101987188B (en) Biological Chinese patent drug for preventing and treating hyperlipoidemia
CN106860495A (en) Fat-reducing liver-protecting Chinese medicine composition
CN104587300A (en) Traditional Chinese medicine composition for treating acute leukemia and preparation method of traditional Chinese medicine composition
CN104096073A (en) Traditional Chinese medicine composition for treating male infertility and preparation method for same
CN103919972B (en) A kind of pharmaceutical composition of resisting fatigue and its preparation method and application
CN1277577C (en) Chinese traditional medicine for treating cerebral thrombosis, preparation method and application
CN108295221B (en) Traditional Chinese medicine composition for treating Parkinson&#39;s disease and preparation method and application thereof
CN106075027B (en) A kind of Chinese medicine composition for treating the proliferation of mammary gland
CN101007147A (en) A dispersible tablet of traditional Chinese medicine composition for treating gastrointestinal diseases and its preparation method
CN105168844A (en) Medicine for treating portal hypertension postoperative treating thrombosis
CN1160110C (en) Chinese medicine for boosting brain and supplementing kidney and its preparation method
CN108524896A (en) A kind of Chinese medicine and preparation method thereof for treating depression
CN104042894A (en) Medicine for treating optic atrophy and preparation method thereof
CN107519237A (en) A kind of pharmaceutical composition for preventing and treating rheumatoid arthritis

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant